Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07854561) titled 'Combination Therapy of Romiplostim and Erythropoiesis-stimulating Agents' on Sept. 28.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Chinese University of Hong Kong
Condition:
Anemia Associated With Chronic Kidney Disease
Intervention:
Drug: Romiplostim
Drug: darbepoetin alfa
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: August 11, 2026
Target Sample Size: 12
Countries of Recruitment:
Hong Kong
To know more, visit https://clinicaltrials.gov/study/NC...